GPON’s mission is to provide a global forum for the recognition of the specialty of oncology nursing, to bridge the gap of disparities in cancer care and to share oncology nurses’ experiences, challenges and successes.
GPON’s vision is to achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all, in the context of cancer care (SDG 3.8).
The Global Power of Oncology Nursing (GPON) conference is held annually as part of London Global Cancer Week, showcasing the nursing contribution to tackling the global burden of cancer. Nurses share their stories, engage in debates, and celebrate their achievements with colleagues from around the world. Most nurse presenters live and work in low- and middle-income countries (LMIC) and focus on solutions to improve cancer care in a world where universal health coverage is far from a reality. Nurses can and do make a huge impact on the burden of cancer, often being the first and only point of care in their communities. However, there is a huge shortage of trained oncology nursing workforce, affecting both the work nurses can do and patient care.
Stay up to date with the latest GPON news and events by joining our mailing list.
GPON will not pass on your submitted information to third parties. You can unsubscribe from our mailing list at anytime.
Chugai Pharmaceutical Co., Ltd. is one of Japan’s leading research-based pharmaceutical companies and has been a member of the Roche Group since 2002.
In Europe, Chugai has been bringing novel therapies to patients since 1993. Headquartered in London, we employ over 250 highly skilled experts in our core areas of oncology, rheumatology and
haematology, to support our growing research pipeline that includes targeted therapies and supportive care agents. Alongside these research activities, our European Partnering Team actively seeks new opportunities to in-licence and commercialise products, working with partners that can benefit from our established cross-functional experience.
Our mission is to dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world. We aim to be a top
innovator for advanced and sustainable patient-centric healthcare, making each patient’s wellbeing our highest priority, whilst pursuing innovation by improving ourselves and thinking differently. We are
also committed to maintaining the highest ethical and moral standards in all we do to create shared value with society.
Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.
Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, USA, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the US, Europe and Japan.
Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.
LEO Pharma is a leader in thrombosis with a specific focus on cancer associated thrombosis.
We have worked with healthcare professionals to care for people with thrombosis for over 80 years. We strive to improve lives with high ethics and holistic support, setting new standards of care.
LEO Pharma headquarters are in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
For more information please visit:
PAXMAN began with one family’s battle against cancer. Sue Paxman was diagnosed with breast cancer and while she was receiving chemotherapy, started to lose her hair.
Now the global expert in preventing chemotherapy-induced alopecia (CIA), PAXMAN address this unmet need in side effect management. Manufacturing and suppling the world leading Paxman Scalp Cooling System (PSCS), PAXMAN has an 80% share of the global scalp-cooling market, with over 4,000 systems installed across 63 countries and continues to conduct research and clinical trials to improve the technology.
CIA is widely recognised as one of the most traumatic side effects associated with chemotherapy treatment; it can have a detrimental impact on a patient’s sense of identity, quality of life and can lead to social isolation.
FDA approved, Scalp Cooling is proven to be efficacious, tolerable and safe by multiple robust studies conducted all over the world. A standard of care at some of the world’s most trusted medical institutions, the treatment is listed on multiple cancer care guidelines and is clinically proven to encourage faster hair regrowth.
In addition, a medical compression and cooling device is under development to prevent chemotherapy-induced nerve damage (CIPN) in hands and feet.